Antiemetic Drugs Market Size, Growth & Trends by 2034

Coverage: By Drug Type (5-HT3 Receptor Antagonists, Dopamine Antagonists, NK1 Receptor Antagonist, Antihistamines, Cannabinoids, Benzodiazepines, Anticholinergics, Others); Application (Chemotherapy, Motion Sickness, Gastroenteritis, Opioid Analgesics, Dizziness, Others), and Geography (North America, Europe, Asia Pacific, and South and Central America)

Historic Data: 2021-2024 | Base Year: 2025 | Forecast Period: 2026-2034
  • Status : Data Released
  • Report Code : TIPRE00020941
  • Category : Life Sciences
  • No. of Pages : 150
  • Available Report Formats : pdf-format excel-format
  • Last update date : April 28, 2026
Antiemetic Drugs Market Size, Growth & Trends by 2034
Report Date: April 28, 2026   |   Report Code: TIPRE00020941 Email: sales@theinsightpartners.com

2025 Market Size

US$ 7.3 Bn

Base year value

2034 Forecast

US$ 12.6 Bn

Projected by 2034

CAGR 2026-2034

6.25 %

Growth rate

Addressable Market

US$ 90.06 Bn

(2026-2034)

The Antiemetic Drugs Market size is expected to reach US$ 12.6 Billion by 2034 from US$ 7.3 Billion in 2025. The market is estimated to record a CAGR of 6.25% from 2026 to 2034.

The Antiemetic Drugs Market report covers analysis by Drug Type (5-HT3 Receptor Antagonists, Dopamine Antagonists, NK1 Receptor Antagonist, Antihistamines, Cannabinoids, Benzodiazepines, Anticholinergics, Others); Application (Chemotherapy, Motion Sickness, Gastroenteritis, Opioid Analgesics, Dizziness, Others), and Geography (North America, Europe, Asia Pacific, and South and Central America). The global analysis is further broken-down at regional level and major countries. The report Offers the Value in US$ for the above analysis and segments.

Purpose of the Report

The report Antiemetic Drugs Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:

  1. Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
  2. Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
  3. Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.

Antiemetic Drugs Market Segmentation

Drug Type

  1. 5-HT3 Receptor Antagonists
  2. Dopamine Antagonists
  3. NK1 Receptor Antagonist
  4. Antihistamines
  5. Cannabinoids
  6. Benzodiazepines
  7. Anticholinergics

Application

  1. Chemotherapy
  2. Motion Sickness
  3. Gastroenteritis
  4. Opioid Analgesics
  5. Dizziness

Market Assessment and Insights

  • Global market for Antiemetic Drugs was valued at US$ 7.30 Billion in 2025
  • Annual market size is expected to reach US$ 12.60 Billion by 2034
  • Total addressable market (TAM) during 2026-2034 is projected to reach approximately US$ 90.06 Billion
  • Market is anticipated to register a CAGR of 6.25% during the forecast period
  • The United States represents a key market, supported by Increasing Frequence of Acute Nausea and Vomiting Disorders, Emerging Cancerous and Chemotherapy Treatments, Increasing Use of Antiemetics for Pregnancy and Motion Sickness, as well as evolving industry dynamics
  • Market analysis covers North America, Europe, Asia-Pacific, South and Central America, Middle East and Africa, with growth evaluated across the forecast period
  • Market opportunities such as Use of Antiemetics for Other Medical Conditions, Research on Pediatric Nausea and Vomiting, Sustainable and Eco-friendly Drug Development are expected to influence market dynamics and addressable market
  • Report profiles industry participants, including GLAXOSMITHKLINE PHARMACEUTICALS LIMITED, JOHNSON AND JOHNSON, SANOFI, MERCK AND CO., NOVARTIS AG, BRISTOL-MYERS SQUIBB, ASTELLAS PHARMA, INC., ELI LILLY AND COMPANY, ABBOTT, CIPLA LTD., DR. REDDY'S LABORATORIES LD, while analyzing competitive strategies and innovation developments
  • Source: The Insight Partners' analysis based on proprietary research, government publications, company annual reports, investor presentations, industry databases, and expert interviews.

● REPORT CUSTOMIZATION

Tailor This Report To Align With Your Specific Business Requirements

This report can be customized to align precisely with your business objectives, scope, and target markets. Customization options include tailored segmentation, geography, competitive analysis, and strategic insights to support informed decision-making.

Customize This Report →

WHAT YOU CAN ADJUST

  • Segmentations
  • Geography
  • Competitive Analysis
  • Language Preferences

Antiemetic Drugs Market: Strategic Insights

antiemetic-drugs-market
  • Get Top Key Market Trends of this report.
    This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Antiemetic Drugs Market Growth Drivers

  1. Increasing Frequence of Acute Nausea and Vomiting Disorders: These increased spells of disorders such as motion sickness, nausea, and vomiting due to a chemotherapeutic agent (CINV), gastrointestinal disorders, and nausea associated with pregnancy may account for one of the most significant factors to the antiemetic drugs market. With the rise of the incidences, the demands for available antiemetics will rise, especially in cases concerning cancer and pregnancy.
  2. Emerging Cancerous and Chemotherapy Treatments: The rising demand for antiemetic drugs in the management of chemotherapy-induced nausea and vomiting (CINV) is blown out by the continued increase in cancer diagnoses worldwide. Such advances in chemotherapy treatments are usually accompanied by side effects such as nausea and vomiting, increasing the demand for drugs to control these symptoms and thus the quality of life in cancer patients.
  3. Increasing Use of Antiemetics for Pregnancy and Motion Sickness: Antiemetics are consumed traditionally for nausea during pregnancy and motion sickness. Pregnancies and traveling are increasing, consequently increasing the demand for this therapy. Interestingly, several safer formulations for pregnant women have opened another growing space in the antiemetics market.

Antiemetic Drugs Market Future Trends

  1. Shift towards Targeted Therapies: A major trend observed is the development of targeted antiemetic therapy, which acts on specific receptors implicated in various pathways of nausea and vomiting. NK1 receptor antagonists and 5-HT3 antagonists are increasingly used because they are more efficient and well-targeted than classical antiemetics, with fewer side effects.
  2. Going for Combination Therapies: An increasing trend is being witnessed in the combination therapy arena to provide a better means to control nausea and vomiting. Combination antiemetic regimens encompassing drugs from various classes, such as serotonin antagonists and corticosteroids, are now widely used in CINV and otherwise, providing better symptom control and patient outcomes.
  3. Rise of Over-the-counter (OTC) Medication: The availability of OTC antiemetic drugs for motion sickness or morning sickness is on the rise. This shift towards self-medication is spurred by increasing customer awareness and greater access. It further extends the market by providing options for patients to manage milder forms of nausea and vomiting.

Antiemetic Drugs Market Opportunities

  1. Use of Antiemetics for Other Medical Conditions: Antiemetics are being used primarily in cancer therapy, treating motion sickness, and for obstetric care but there is an interest in exploring their use in treating other medical conditions such as gastroparesis, viral infections, and postoperative nausea. For these new indications, there exist unexplored opportunities that widen the scope of antiemetic use.
  2. Research on Pediatric Nausea and Vomiting: Nausea and vomiting in children can be a challenge because of gastroenteritis, chemotherapy, or motion sickness. This presents a marketing opportunity for developing safe and effective antiemetics for the pediatric market. This area allows those companies working in the pediatric space to capitalize on an underdeveloped market.
  3. Sustainable and Eco-friendly Drug Development: There is an opportunity for developing environmentally friendly antiemetic preparations with a reduced environmental impact as more and more patients and healthcare providers are demanding the use of sustainable products. Biodegradable formulation and eco-friendly packaging are becoming prominent considerations in formulating newer therapies, providing an opportunity for differentiation in the marketplace.

Antiemetic Drugs Market Report Scope

Report Attribute Details
Market size in 2025 US$ 7.3 Billion
Market Size by 2034 US$ 12.6 Billion
Global CAGR (2026 - 2034) 6.25%
Historical Data 2021-2024
Forecast period 2026-2034
Segments Covered By Drug Type
  • 5-HT3 Receptor Antagonists
  • Dopamine Antagonists
  • NK1 Receptor Antagonist
  • Antihistamines
  • Cannabinoids
  • Benzodiazepines
  • Anticholinergics
By Application
  • Chemotherapy
  • Motion Sickness
  • Gastroenteritis
  • Opioid Analgesics
  • Dizziness
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • GLAXOSMITHKLINE PHARMACEUTICALS LIMITED
  • JOHNSON AND JOHNSON
  • SANOFI
  • MERCK AND CO.
  • NOVARTIS AG
  • BRISTOL-MYERS SQUIBB
  • ASTELLAS PHARMA, INC.
  • ELI LILLY AND COMPANY
  • ABBOTT
  • CIPLA LTD.
  • DR. REDDY'S LABORATORIES LD

Antiemetic Drugs Market Players Density: Understanding Its Impact on Business Dynamics

The Antiemetic Drugs Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

antiemetic-drugs-market-cagr

Key Selling Points

  1. Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Antiemetic Drugs Market, providing a holistic landscape.
  2. Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
  3. Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
  4. Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.

The research report on the Antiemetic Drugs Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.


Frequently Asked Questions

The major factors driving the Antiemetic Drugs Market are Increasing Frequence of Acute Nausea and Vomiting Disorders, Emerging Cancerous and Chemotherapy Treatments, and Increasing Use of Antiemetics for Pregnancy and Motion Sickness

The key future trends of the market are Shift towards Targeted Therapies, Going for Combination Therapies, and Rise of Over-the-counter (OTC) Medication

The leading players operating in the Antiemetic Drugs Market include GLAXOSMITHKLINE PHARMACEUTICALS LIMITED, JOHNSON AND JOHNSON, SANOFI, MERCK AND CO., NOVARTIS AG, BRISTOL-MYERS SQUIBB, ASTELLAS PHARMA, INC., ELI LILLY AND COMPANY, ABBOTT, CIPLA LTD., DR. REDDY'S LABORATORIES LD

The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.

Some of the customization options available based on the request are an additional 3-5 company profiles and country-specific analysis of 3-5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
Mrinal Kerhalkar
Manager,
Market Research & Consulting

Mrinal is a seasoned research analyst with over 8 years of experience in Life Sciences Market Intelligence and Consulting. With a strategic mindset and unwavering commitment to excellence, she has built deep expertise in pharmaceutical forecasting, market opportunity assessment, and developing industry benchmarks. Her work is anchored in delivering actionable insights that empower clients to make informed strategic decisions.

Mrinal’s core strength lies in translating complex quantitative datasets into meaningful business intelligence. Her analytical acumen is instrumental in shaping go-to-market (GTM) strategies and uncovering growth opportunities across the pharmaceutical and medical device sectors. As a trusted consultant, she consistently focuses on streamlining workflow processes and establishing best practices, thereby driving innovation and operational efficiency for her clients.

  • Comprehensive Market Sizing and Forecast Analysis
  • Detailed Segmentation Analysis
  • In-Depth Market Dynamics Assessment
  • Regional and Country-Level Insights
  • Competitive Landscape and Company Benchmarking
  • Strategic Business Intelligence

Testimonials

Reason to Buy

  • Informed Decision-Making
  • Understanding Market Dynamics
  • Competitive Analysis
  • Identifying Emerging Markets
  • Customer Insights
  • Market Forecasts
  • Risk Mitigation
  • Boosting Operational Efficiency
  • Strategic Planning
  • Investment Justification
  • Tracking Industry Innovations
  • Aligning with Regulatory Trends
Sales Assistance
US: +1-646-491-9876
UK: +44-20-8125-4005
DUNS Logo
ISO Certified Logo
GDPR
CCPA